DE60233738D1 - Hemmung des apoptoseprozesses und verbesserung der zelleistung - Google Patents
Hemmung des apoptoseprozesses und verbesserung der zelleistungInfo
- Publication number
- DE60233738D1 DE60233738D1 DE60233738T DE60233738T DE60233738D1 DE 60233738 D1 DE60233738 D1 DE 60233738D1 DE 60233738 T DE60233738 T DE 60233738T DE 60233738 T DE60233738 T DE 60233738T DE 60233738 D1 DE60233738 D1 DE 60233738D1
- Authority
- DE
- Germany
- Prior art keywords
- cell
- apoptose
- inhibition
- improvement
- cell performance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000034615 apoptosis-related disease Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 2
- 238000003782 apoptosis assay Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000005522 programmed cell death Effects 0.000 abstract 2
- 238000002659 cell therapy Methods 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30381301P | 2001-07-10 | 2001-07-10 | |
PCT/US2002/021606 WO2003006607A2 (en) | 2001-07-10 | 2002-07-10 | Inhibition of apoptosis process and improvement of cell performance |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60233738D1 true DE60233738D1 (de) | 2009-10-29 |
Family
ID=23173824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60233738T Expired - Lifetime DE60233738D1 (de) | 2001-07-10 | 2002-07-10 | Hemmung des apoptoseprozesses und verbesserung der zelleistung |
Country Status (13)
Country | Link |
---|---|
US (1) | US7604989B2 (de) |
EP (1) | EP1414948B1 (de) |
JP (2) | JP4435563B2 (de) |
KR (1) | KR20040044433A (de) |
CN (1) | CN1526011A (de) |
AT (1) | ATE443131T1 (de) |
AU (1) | AU2002315534B2 (de) |
CA (1) | CA2452005C (de) |
DE (1) | DE60233738D1 (de) |
MX (1) | MXPA04000281A (de) |
NO (1) | NO20040101L (de) |
WO (1) | WO2003006607A2 (de) |
ZA (2) | ZA200508985B (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7812148B2 (en) | 2001-04-05 | 2010-10-12 | Millipore Corporation | Vectors comprising CpG islands without position effect varigation and having increased expression |
KR100454016B1 (ko) * | 2002-01-05 | 2004-10-26 | 한국과학기술원 | 항예정사 유전자로 형질전환되고 dhfr 유전자가결핍된 신규한 cho 세포주, 그의 제조 방법 및 상기형질전환된 cho 숙주 세포를 이용한 목적단백질의 생산방법 |
CA2514412A1 (en) | 2003-02-01 | 2004-08-12 | Innovata Plc | Improved genetic elements providing high levels of expression |
JP4825518B2 (ja) * | 2003-10-24 | 2011-11-30 | 一般財団法人化学及血清療法研究所 | 新規なタンパク質高産生組換え動物細胞、その作製方法及びそれを用いたタンパク質を大量産生する方法 |
EP1702071B1 (de) * | 2003-12-31 | 2012-02-22 | Kalobios Inc. | Transaktivierungssystem für säugerzellen |
US7608425B2 (en) * | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
US7537930B2 (en) | 2004-07-23 | 2009-05-26 | Immunomedics, Inc. | Mammalian cell lines for increasing longevity and protein yield from a cell culture |
AU2005333513B2 (en) * | 2004-07-23 | 2011-06-02 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
WO2007015691A2 (en) * | 2004-07-23 | 2007-02-08 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
US7531327B2 (en) * | 2004-07-23 | 2009-05-12 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
GB0509965D0 (en) | 2005-05-17 | 2005-06-22 | Ml Lab Plc | Improved expression elements |
WO2007119774A1 (ja) * | 2006-04-13 | 2007-10-25 | Chugai Seiyaku Kabushiki Kaisha | タウリントランスポーター遺伝子 |
WO2007124106A2 (en) * | 2006-04-21 | 2007-11-01 | Bayer Healthcare Llc | Application of antl-apoptotic genes in mammalian cells for perfusion culture. |
CN101802170A (zh) * | 2007-01-08 | 2010-08-11 | 米利波尔公司 | 在存在降低水平的一或多种污染物的条件下制备重组蛋白的细胞培养方法 |
CA2727010C (en) | 2008-06-13 | 2017-05-16 | Centocor Ortho Biotech Inc. | Methods for improving viability and productivity in cell culture |
WO2011056886A2 (en) * | 2009-11-03 | 2011-05-12 | The Johns Hopkins University | Method and composition for generating programmed cell death resistant algal cells |
HUP1000243A2 (en) | 2010-05-06 | 2012-01-30 | Avidin Kft | 8-hidroxy-quinoline derivatives |
KR20200002050A (ko) | 2018-06-28 | 2020-01-08 | 삼성디스플레이 주식회사 | 유기 발광 표시 장치 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
ATE236987T1 (de) * | 1992-11-13 | 2003-04-15 | Idec Pharma Corp | Konsensus-kozak-sequenzen zur säugetier- exprimierung |
US5565491A (en) * | 1994-01-31 | 1996-10-15 | Bristol-Myers Squibb Company | Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation |
US5550050A (en) * | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6087129A (en) * | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
US5897992A (en) * | 1996-09-27 | 1999-04-27 | Cold Spring Harbor Laboratory | Cell-free assay using oncogene-induced apoptosis in drug-resistant cells |
US6011138A (en) * | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
NZ510357A (en) * | 1998-08-07 | 2004-02-27 | Immunex Corp | Molecules designated B7L-1 |
US6570002B1 (en) | 1999-02-26 | 2003-05-27 | The Johns Hopkins University | Inhibitor of programmed cell death |
US6140118A (en) * | 1999-08-11 | 2000-10-31 | Wisconsin Alumni Research Foundation | Avian blastodermal cell lines |
EP1650307B1 (de) * | 1999-09-27 | 2010-07-14 | Genentech, Inc. | Verfahren zur Herstellung von rekombinanten Proteinen mittels Inhibitoren von Apoptose |
AU781552B2 (en) * | 1999-11-12 | 2005-05-26 | Merck Sharp & Dohme Corp. | Diaryl piperidyl pyrrole derivatives as antiprotozoal agents |
KR100454016B1 (ko) | 2002-01-05 | 2004-10-26 | 한국과학기술원 | 항예정사 유전자로 형질전환되고 dhfr 유전자가결핍된 신규한 cho 세포주, 그의 제조 방법 및 상기형질전환된 cho 숙주 세포를 이용한 목적단백질의 생산방법 |
EP1348758A1 (de) | 2002-03-28 | 2003-10-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Wirtszellen mit verbessertem Überleben und Verfahren zur Herstellung von diesen Zellen |
-
2002
- 2002-07-10 CA CA2452005A patent/CA2452005C/en not_active Expired - Fee Related
- 2002-07-10 AU AU2002315534A patent/AU2002315534B2/en not_active Ceased
- 2002-07-10 EP EP02742400A patent/EP1414948B1/de not_active Expired - Lifetime
- 2002-07-10 JP JP2003512366A patent/JP4435563B2/ja not_active Expired - Fee Related
- 2002-07-10 KR KR10-2004-7000349A patent/KR20040044433A/ko not_active Application Discontinuation
- 2002-07-10 WO PCT/US2002/021606 patent/WO2003006607A2/en active Application Filing
- 2002-07-10 DE DE60233738T patent/DE60233738D1/de not_active Expired - Lifetime
- 2002-07-10 AT AT02742400T patent/ATE443131T1/de not_active IP Right Cessation
- 2002-07-10 CN CNA028138511A patent/CN1526011A/zh active Pending
- 2002-07-10 ZA ZA200508985A patent/ZA200508985B/xx unknown
- 2002-07-10 MX MXPA04000281A patent/MXPA04000281A/es not_active Application Discontinuation
- 2002-07-10 US US10/191,052 patent/US7604989B2/en not_active Expired - Fee Related
-
2004
- 2004-01-08 ZA ZA200400137A patent/ZA200400137B/xx unknown
- 2004-01-09 NO NO20040101A patent/NO20040101L/no not_active Application Discontinuation
-
2009
- 2009-02-04 JP JP2009024345A patent/JP2009118851A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1414948A4 (de) | 2006-06-21 |
AU2002315534B2 (en) | 2008-05-22 |
US7604989B2 (en) | 2009-10-20 |
JP2005525782A (ja) | 2005-09-02 |
ZA200508985B (en) | 2006-07-26 |
ATE443131T1 (de) | 2009-10-15 |
WO2003006607A2 (en) | 2003-01-23 |
JP2009118851A (ja) | 2009-06-04 |
ZA200400137B (en) | 2006-06-28 |
CA2452005C (en) | 2011-03-15 |
WO2003006607A9 (en) | 2003-04-10 |
CN1526011A (zh) | 2004-09-01 |
JP4435563B2 (ja) | 2010-03-17 |
NO20040101L (no) | 2004-03-09 |
MXPA04000281A (es) | 2004-07-23 |
EP1414948B1 (de) | 2009-09-16 |
EP1414948A2 (de) | 2004-05-06 |
WO2003006607A3 (en) | 2003-07-31 |
CA2452005A1 (en) | 2003-01-23 |
US20030064510A1 (en) | 2003-04-03 |
KR20040044433A (ko) | 2004-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60233738D1 (de) | Hemmung des apoptoseprozesses und verbesserung der zelleistung | |
EP1444329A4 (de) | Sich in schlagende kardiomyozyten verwandelnde stammzellen | |
TW200501976A (en) | Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto | |
YU40402A (sh) | 4-pirimidinil-n-acil-l-fenilalanini | |
TW200505939A (en) | Process for production of cyclic peptides | |
IL144636A0 (en) | Thioamide derivatives | |
DE60332358D1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
NO974943L (no) | Angiostatinfragmenter, aggregert angiostatin og anvendelse derav | |
BR0212482A (pt) | Método para produzir uma tira de aço elétrico de grão orientado | |
MXPA03002778A (es) | Polipeptidos antiangiogenicos y metodos para inhibir angiogenesis. | |
HK1041476B (zh) | 抑制細胞粘附的抗炎和免疫抑制化合物 | |
JO2281B1 (en) | Phenylalanine-L-acyl-N-pyridine-4 | |
ES2164653T3 (es) | Procedimiento para producir heterociclos polihidroxilicos que contienen nitrogeno n-sustituidos. | |
AU3052799A (en) | Pharmaceutical compositions comprising erythropoietin for treatment of cancer | |
HRP20040781A2 (en) | Process for the preparation of high purity perindopril and intermediates useful in the synthesis | |
HUP0402165A2 (hu) | Nem neurotoxikus plazminogén aktiváló faktorok a szélhűdés kezelésére | |
EP1479776A4 (de) | Zellextrakt für die zellfreie proteinsynthese und verfahren zur herstellung davon | |
HUP0500029A3 (en) | Production process of recombinant placental growth factor | |
EP1661989A4 (de) | Verfahren zur herstellung einer rekombinanten zelle mit hohem fibrinogenproduktionsvermögen und zelle mit hohem produktionsvermögen | |
PL374504A1 (en) | 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | |
YU72603A (sh) | Proizvodnja i izdvajanje indolokarbazol glikozida | |
CA102062S (en) | Bun for hamburgers | |
WO2004045652A3 (en) | Biocompatible magnetic materials for the treatment of cancer by means of hyperthermia, and processes for their production | |
AU2003301260A8 (en) | Novel methods for the production of cloned mammals, mammals cloned according to the methods, and methods of use of same | |
TWI316091B (de) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |